Find
News Releases
= add release to Briefcase
| All Releases | |||
|---|---|---|---|
 |
Adoption of Drug-Eluting Stents Associated With Lower Health Care Costs and Improved Clinical Outcomes Oct 23, 2007 |
11.2 KB |
|
|
Washington, DC (October 23, 2007) – The introduction of drug-eluting stents (DES) was associated with reduced health care costs while providing improved clinical outcomes compared to the pre-DES era according to data presented here today at the annual Transcatheter Cardiovascular Therapeutics 2007. "These results suggest that me... |
|||
|
Next Generation New Devices to Treat Clogged Neck Arteries Launched in U.S. and Europe Oct 23, 2007 |
7.6 KB |
|
|
Washington, D.C. (October 23, 2007) – Cordis Corporation today announced the U.S. and European launch of Cordis' next generation carotid stent system, the PRECISE® PRO RX™ Nitinol Self-Expanding Stent, to treat clogged neck arteries. The worldwide launch of the Cordis carotid system was announced today at the Transcatheter Cardi... |
|||
|
New Long-Term Data Suggest Clinical Differences in Safety and Efficacy Between CYPHER® Sirolimus-Eluting Coronary Stent and Taxus Stent Oct 22, 2007 |
10.9 KB |
|
|
Washington DC (October 22, 2007) – An analysis of fifteen-month data from the Western Denmark Heart Registry found that patients who received the CYPHER® Sirolimus-eluting Coronary Stent had a lower risk of blood clots (stent thrombosis) and were less likely to need another procedure at the same lesion site (target lesion revasculari... |
|||
|
New Study Shows Excellent Outcomes for CYPHER® Sirolimus-Eluting Coronary Stent in Treatment of Completely Blocked Coronary Arteries Oct 21, 2007 |
10.9 KB |
|
|
Washington, DC (October 21, 2007) – Implantation of the CYPHER® Sirolimus-eluting Coronary Stent to treat completely blocked coronary arteries led to substantial reductions in recurrent blockage and the need for repeat treatment compared to bare metal stents in a study presented today at the Transcatheter Cardiovascular Therapeutics ... |
|||
|
Cordis Corporation Announces Clinical Studies And Events At TCT 2007 Oct 17, 2007 |
11.9 KB |
|
|
Warren, NJ (October 17, 2007) – Cordis Corporation will present clinical data and professional education opportunities at the annual Transcatheter Cardiovascular Therapeutics 2007 meeting (TCT 2007), which will take place in Washington, DC from October 20 to 25. Data from several studies will highlight the CYPHER® Sirolimus-eluting... |
|||
|
Johnson & Johnson Launches Global Diabetes Institute to Provide State-of-The- Art Education, Training to Health Professionals Oct 16, 2007 |
9.0 KB |
|
|
NEW BRUNSWICK, N.J., Oct 16, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Johnson & Johnson (NYSE: JNJ) today announced the establishment of the Johnson & Johnson Diabetes Institute (JJDI) to transform diabetes care by providing comprehensive training on the latest practice standards, new diabetes tools and technologies and reimbursement ... |
|||
|
Johnson & Johnson Reports 2007 Third-Quarter Results: Sales of $15.0 Billion Increased 12.7%; EPS was $.88, Including Special Charges; Excluding Special Charges, EPS was $1.06 * Oct 16, 2007 |
28.3 KB |
|
|
NEW BRUNSWICK, N.J., Oct 16, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Johnson & Johnson (NYSE: JNJ) today announced third-quarter sales of $15.0 billion, an increase of 12.7% as compared to the third quarter of 2006. Operational growth was 9.7% and currency contributed 3.0%. Domestic sales were up 5.8%, while international sales incre... |
|||
|
FDA Approves DORIBAX™ for the Treatment of Complicated Intra-Abdominal and Complicated Urinary Tract Infections Oct 15, 2007 |
12.3 KB |
|
|
Raritan, NJ (October 15, 2007) - The U.S. Food and Drug Administration (FDA) has approved DORIBAX™ (doripenem for injection) as a new treatment for complicated intra-abdominal and complicated urinary tract infections, including pyelonephritis. DORIBAX™ has demonstrated activity against a wide range of Gram-positive1 and Gr... |
|||
|
INVEGA(TM) Significantly Reduced Symptoms of Schizophrenia Compared to SEROQUEL(R) in Acutely Ill, Hospitalized Patients Oct 13, 2007 |
14.0 KB |
|
|
ORLANDO, Fla., Oct 13, 2007 /PRNewswire via COMTEX News Network/ -- Acutely ill, hospitalized patients with schizophrenia showed significant improvement in symptoms after taking INVEGA(TM) (paliperidone) Extended-Release Tablets as compared to SEROQUEL(R)(a) (quetiapine) and placebo. Symptom improvement was observed with INVEGA as early as five day... |
|||
|
McNeil Consumer Healthcare Is Voluntarily Withdrawing Infants' Cough And Cold Products: CONCENTRATED TYLENOL® INFANTS' DROPS PLUS COLD, CONCENTRATED TYLENOL® INFANTS' DROPS PLUS C Oct 11, 2007 |
7.9 KB |
|
|
Fort Washington, PA (October 11, 2007) – McNeil Consumer Healthcare, a division of McNeil-PPC, Inc., announced today that the company is voluntarily withdrawing certain infants' cough and cold products from the market. When used as directed, these medicines are generally recognized as safe and effective. While most parents use these medic... |
|||
|
Johnson & Johnson to Host Analyst Meeting to Discuss Third-Quarter Financial Results and Review Its Medical Device & Diagnostics Business Oct 10, 2007 |
6.4 KB |
|
|
NEW BRUNSWICK, N.J., Oct 10, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Johnson & Johnson will host an analyst meeting at 8:30 a.m. (Eastern Time) on Tuesday, October 16, 2007, to discuss third-quarter financial results and review its Medical Device & Diagnostics business. Nick Valeriani, Worldwide Chairman, Medical Devices & Diagnostic... |
|||
|
New HARMONIC FOCUS™ Provides Advantages in Surgical Efficiency, Performance and Patient Outcomes Oct 9, 2007 |
10.4 KB |
|
|
NEW ORLEANS, LOUISIANA (October 8, 2007) – Ethicon Endo-Surgery announced today at the American College of Surgeons 93rd Annual Clinical Conference the launch of the HARMONIC FOCUS Curved Shears, a new 9 cm advanced energy device specifically designed for fine and delicate dissections in open surgeries. The HARMONIC FOCUS... |
|||
|
New Data Show Ceftobiprole as Effective as Combination Therapy in Treating Patients with Diabetic Foot Infections Oct 8, 2007 |
10.6 KB |
|
|
RARITAN, N.J., Oct 08, 2007 /PRNewswire via COMTEX News Network/ -- Johnson & Johnson Pharmaceutical Research & Development, L.L.C. today announced results from a Phase III trial that showed that investigational antibiotic ceftobiprole was found to clinically cure 86% of patients with diabetic foot infections -- including some infections that were ... |
|||
|
Topline Findings from Comparative Analysis of INVEGA(TM) and Quetiapine in Schizophrenia to be Postered at the 20th Annual U.S. Psychiatric and Mental Health Congress Oct 8, 2007 |
10.2 KB |
|
|
TITUSVILLE, N.J., Oct 08, 2007 /PRNewswire via COMTEX News Network/ -- Preliminary results from a clinical study comparing INVEGA(TM) (paliperidone) Extended-Release Tablets to quetiapine (marketed as Seroquel(R)) and placebo in patients with recent, acute exacerbation of schizophrenia will be the subject of a poster on display during the 20th Annu... |
|||
|
Ortho-Clinical Diagnostics Introduces Improved Sensitivity Troponin I Assay To Help Diagnose Heart Attack, Heart Damage Oct 3, 2007 |
8.7 KB |
|
|
Raritan, NJ (October 1, 2007) – Ortho-Clinical Diagnostics, a Johnson & Johnson company, announces the availability in the United States, Europe and other international markets1 of an improved sensitivity troponin I assay. The biomarker troponin I is used along with other cardiac tests to help diagnose a heart attack and to det... |
|||
|
Statement of DePuy Orthopaedics, Inc. Regarding Agreement with U.S. Attorney's Office Sep 27, 2007 |
6.5 KB |
|
|
WARSAW, Ind., Sept 27, 2007 /PRNewswire via COMTEX News Network/ -- As part of an industry-wide settlement affecting the five major orthopaedics manufacturers, DePuy Orthopaedics, Inc. has entered into an agreement with the United States Attorney's Office that resolves a previously reported government investigation into sales practices in the ortho... |
|||
|
Pivotal Ustekinumab (CNTO 1275) Phase 3 Data to Debut at World Congress of Dermatology Meeting Sep 25, 2007 |
7.5 KB |
|
|
HORSHAM, Pa., Sept. 25 /PRNewswire/ -- Findings from an international, multicenter, randomized, double-blind, placebo-controlled Phase 3 trial evaluating ustekinumab (CNTO 1275) in the treatment of moderate to severe plaque psoriasis will be presented for the first time at the 21st meeting of the World Congress of Dermatology, which ta... |
|||
|
FDA Accepts New Drug Application For Priority Review Of Investigational HIV Treatment TMC125 Sep 20, 2007 |
8.0 KB |
|
|
Yardley, PA (September 20, 2007) – Tibotec Pharmaceuticals Ltd. today announced that the New Drug Application (NDA) for TMC125 (etravirine), an investigational non-nucleoside reverse transcriptase inhibitor (NNRTI), has been accepted for priority review by the United States Food and Drug Administration (FDA). The Prescription Drug User Fe... |
|||
|
Johnson Statement on Litigation with the American Red Cross Sep 20, 2007 |
5.5 KB |
|
|
New Brunswick, NJ (September 20, 2007) - Johnson & Johnson has historically been, and continues to be, one of the strongest corporate supporters of the American Red Cross (ARC) and its humanitarian mission. We appreciate and have great respect for the relief work of the ARC and, despite our current disagreement about our trademarks, wi... |
|||
|
New Phase 3 Study In Treatment-Naïve Adults With HIV Evaluates Efficacy And Safety Of Once-Daily PREZISTA™/Ritonavir Vs. Kaletra® As Part Of HIV Combination Therapy Sep 18, 2007 |
16.6 KB |
|
|
Bridgewater, NJ (September 18, 2007) – Results from a new ongoing, randomized, controlled, open-label Phase 3 study showed that 84 percent of treatment-naïve HIV-1 infected adults taking an investigational dose of PREZISTA™ (darunavir) 800 mg (two 400 mg tablets) with 100 mg ritonavir once daily with TRUVADA®1 (emtricitabine... |
|||
= add release to Briefcase
